IMforte: Maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer (SCLC) vs atezolizumab alone.

DeLLphi-304: Phase 3 of tarlatamab vs chemotherapy for SCLC after progression on platinum-based therapy.

DeLLphi?303: Tarlatamab with first?line chemo?immunotherapy for ES?SCLC.

Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage SCLC — Primary Analysis of Phase 2 IDeate?Lung01 (Oral Abstract OA06.03)

Distinct Clinical and Biological Features of Five SCLC Subtypes Identified by Plasma Proteomic Analysis

Panel Discussion: Based on the Above Topics

Transforming the SCLC Treatment Paradigm with Durvalumab

Non-Squamous mNSCLC the way forward The Breakthrough of Immunotherapy

Panel Discussion: Optimizing ALK TKI Selection for Holistic Management of ALK+ mNSCLC Dr

Immuno-Oncology in Motion: Tislelizumab Promise for Lung Carcinoma

Treatment Evolution of Squamous Non-small Cell Lung Cancer

Unmet supportive care needs in patients with advanced cancer and its impact on distress

Comparative effectiveness of pharmacological and non-pharmacological interventions for dyspnea management in advanced cancer: A systematic review and network meta-analysis

Pilot Feasibility Trial of a Supportive Care Digital Application for Patients with Advanced Non-Small Cell Lung Cancer

Frailty in motion: How Fitbit data reflects patients with cancers' functional status in the All-of-Us database

Panel Discussion: Based on the Above Topics